Hsbc Holdings PLC I Mab Transaction History

Hsbc Holdings PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$8.27 - $18.43 $688,684 - $1.53 Million	-83,275 Reduced 60.74%	53,835 $594,000
Q1 2022 May 16, 2022	BUY	$12.54 - $46.93 $555,985 - $2.08 Million	44,337 Added 47.79%	137,110 $2.24 Million
Q4 2021 Feb 11, 2022	SELL	$45.28 - $74.5 $213,268 - $350,895	-4,710 Reduced 4.83%	92,773 $4.4 Million
Q3 2021 Nov 12, 2021	BUY	$57.18 - $84.43 $3.12 Million - $4.6 Million	54,532 Added 126.96%	97,483 $7.07 Million
Q2 2021 Aug 13, 2021	BUY	$47.86 - $83.95 $1.41 Million - $2.47 Million	29,456 Added 218.27%	42,951 $3.61 Million
Q1 2021 May 14, 2021	SELL	$44.38 - $63.97 $5,547 - $7,996	-125 Reduced 0.92%	13,495 $654,000
Q4 2020 Feb 12, 2021	BUY	$32.94 - $47.15 $98 - $141	3 Added 0.02%	13,620 $642,000
Q3 2020 Nov 12, 2020	BUY	$27.46 - $47.03 $373,922 - $640,407	13,617 New	13,617 $628,000

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $78.9M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Hsbc Holdings PLC with notifications on news.